Hertility
Biotechnology ResearchEngland, United Kingdom51-200 Employees
Hertility is a London, England-based biotechnology research company with 51-200 employees and revenue in the range of $1M-$10M, described as being built by women, for women. It develops diagnostic testing that provides data-driven insights into reproductive health, fertility decline, and menopause onset, and offers expert advice, education, and access to care remotely from home. Through research trials, it aims to shorten time to diagnosis by combining at-home testing with specialist gynecological care and tailors pathways to individual reproductive goals, including ovarian health, fertility options, and conditions such as PCOS. The firm currently diagnoses nine common gynecological pathologies that may affect fertility and signposts gynecologic cancers. Milestones include the October 2025 launch of GYN-AI, a clinical-grade diagnostic tool, and a March 2026 partnership with NVIDIA to develop a foundational AI platform.